What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).”In the company’s words, NCT04519749 on ClinicalTrials.gov
- Tested for
- Fabry Disease (2 trials)
- Main trialPhase 1/2
- “This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.”In the company’s words, NCT04519749 on ClinicalTrials.gov
Other drugs for Fabry Disease
- Migalastat HClAmicus Therapeutics · Phase 3
- Pegunigalsidase alfaChiesi Farmaceutici S.p.A. · Protalix · Phase 2/3
- LucerastatIdorsia Pharmaceuticals Ltd. · Phase 3
- Agalsidase betaSanofi · Phase 3
- GZ/SAR402671Sanofi · Phase 3
- AMT-191UniQure Biopharma B.V. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Jan 2026 | An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease | |
| Phase 1/2Recruiting | Jun 2026 | 4D-310 in Adults With Fabry Disease and Cardiac Involvement |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026